Dantrolene

For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.

Active substance: Dantrolene

Examples of brand names: Dantamacrin [DE]

ATC code: M03CA01

Main use (for orientation): Spasticity; malignant hyperthermia

Documented research summary

Within the documented search scope, no sufficiently attributable cannabinoid pair is established for Dantrolene. The structured assessment distinguishes documented drug context from the absence of specific interaction evidence. Missing data do not establish safety.

Uncertainties and limitations

Oral use; the add-on study is not a pair experiment. Repeat abstract retrieval unsuccessful; full text not reassessed. Do not independently change prescribed medicines on the basis of this research dataset.

Structured assessment

Category: Drug context

Cannabinoid scope: No specifically substantiated pair involving a registered cannabinoid in the material assessed; no claim that all 28 cannabinoids were comprehensively reviewed simultaneously.

Evidence status: Drug properties supported by product information; insufficient evidence for a specific cannabinoid–drug pair effect.

Mechanism / drug context: Hepatic microsomal metabolism; weakness, drowsiness and liver risks are properties of oral dantrolene, not an established cannabinoid effect.

Type of supporting material: Product information and documented individual literature screening; no clinical pair trial approved for use as evidence.

Clinical interpretation: An additionally sedating or hepatically burdensome combination cannot be quantified from these data.

Context: The nabiximols study allowed dantrolene as concomitant medication but provides no isolated dantrolene–cannabinoid analysis.

Drug context and gaps in search results are not measured interactions. The source role below describes which statement the source actually supports.

Source role [V2_LABEL_D0178]: Original product information: drug context, not evidence for a cannabinoid–drug pair

Statement supported: Hepatic microsomal metabolism; weakness, drowsiness and liver risks are properties of oral dantrolene, not an established cannabinoid effect.

Source: DANTRIUM (DANTROLENE SODIUM) CAPSULE [PAR HEALTH USA, LLC] [V2_LABEL_D0178]

Source role [CA_P_39106541]: Study context, not isolated pair evidence

Statement supported: Nabiximols add-on study with permitted concomitant medication; no separately reported dantrolene effect.

Source: A randomized, double-blind, placebo-controlled trial to evaluate the effect of nabiximols oromucosal spray on clinical measures of spasticity in patients with multiple sclerosis. [CA_P_39106541]

Scope of review: Individual research with documented title/abstract screening and targeted review of original sections. This is not exhaustive evidence that interactions are absent.

Unresolved source question: All individual review fields read. Original product information was rechecked only in the relevant pharmacokinetic/interaction excerpts; no complete recertification of all labels or worldwide full-text search. Literature access was based on the previously documented review; only the listed web sources were additionally read in this round. Oral use; the add-on study is not a pair experiment. Repeat abstract retrieval unsuccessful; full text not reassessed.

Separately recorded findings

No separately substantiated finding for this drug–cannabinoid pair is recorded within the documented scope of review. This does not prove that no such study exists anywhere or that the combination is safe.

References and access status

[V2_LABEL_D0178] DANTRIUM (DANTROLENE SODIUM) CAPSULE [PAR HEALTH USA, LLC]

Original source / bibliographic reference

Authors: Par Health USA, LLC

Year: 2026

Source type: Official US SPL / DailyMed

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

[CA_P_39106541] A randomized, double-blind, placebo-controlled trial to evaluate the effect of nabiximols oromucosal spray on clinical measures of spasticity in patients with multiple sclerosis.

Original source / bibliographic reference

Authors: Bethoux FA, Farrell R, Checketts D, Sahr N, Berwaerts J, Alexander JK, Skobieranda F.

Year: 2024

Source type: Primary / secondary publication; design and use described in the individual review

DOI: 10.1016/j.msard.2024.105740

PMID: 39106541

Source access – 23 October 2026: Direct retrieval could not be fully verified; availability remains unresolved.

Bibliographic attribution or source identity cross-checked.

DOI – publisher access (access restrictions may apply)

Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.

Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility